Clinical trials for Kidney cancer

118 currently recruiting clinical trials
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05875168 #2023-507937-14-00
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05410145 #2023-508517-16-00
Locally Advanced Metastatic Metastatic Castration-resistant KRAS G12C 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
D3 Bio (Wuxi) Co., Ltd
Phase 1 / Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06726148 #2024-517281-42-00
Phase I - cancer amplifié CCNE1
Locally Advanced Metastatic Other mutation 1 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
Novartis
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06669117 #2024-512760-64-00
Partie 1 (Escalade de dose)
Locally Advanced Metastatic Metastatic Castration-resistant MET 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06188702 #2025-521249-25-00
Phase 1 Dose Escalation
Locally Advanced Metastatic MTAP 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Servier
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06188702 #2025-521249-25-00
Cohort Basket - autres tumeurs
Locally Advanced Metastatic MTAP 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Servier
Phase 1 / Phase 2 Kidney cancer #NCT07049926 #2024-516437-12-00
Clear cell carcinoma Locally Advanced Metastatic None Immunotherapy Systemic Treatment-Naive
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Kidney cancer #NCT05706129 #2023-504254-35-00
Other Localized None Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA
Phase 1 / Phase 2 Kidney cancer #NCT05706129 #2023-504254-35-00
Clear cell carcinoma Locally Advanced Metastatic 2 3 or more Targeted therapy Immunotherapy Targeted therapy
8 recruiting sites
Debiopharm International SA
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06220864 #2025-520557-36-00
Escalade et extension de dose monothérapie et escalade de dose combinaison
Locally Advanced Metastatic Metastatic Castration-resistant 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Synnovation Therapeutics, Inc.